Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias

Archives of Internal Medicine

Volumn 159, Issue 1, 1999, Pages 65-70

  Bloemenkamp, Kitty W M ^a   Rosendaal, Frits R ^a   Büller, Harry R ^b   Helmerhorst, Frans M ^a   Colly, Louisa P ^c   Vandenbroucke, Jan P ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Amsterdam Thrombosis Service   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CONTRACEPTION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VEIN THROMBOSIS;

ADOLESCENT; ADULT; BIAS (EPIDEMIOLOGY); CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LEG; MIDDLE AGED; NETHERLANDS; ODDS RATIO; REFERRAL AND CONSULTATION; RISK FACTORS; VENOUS THROMBOSIS;

EID: 0033545177     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.1.65     Document Type: Article

References (39)

1. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Evidence that currently available pills are associated with cardiovascular disease: venous disease. In: Hannaford PC, Webb AMC, eds. Evidence-Guided Prescribing of the Pill. Carnforth, United Kingdom: Parthenon Publishing; 1996:61-76.
2. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet. 1995;346:1575-1582.
3. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995;346:1589-1593.
4. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD, on behalf of the Transnational Research Group on Oral Contraceptives and the Health of Young Women. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ. 1996;312: 83-88.
5. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet. 1995;346:1582-1588.
6. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen. Lancet. 1995;346:1593-1596.
7. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453-1457.
8. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. BMJ. 1968;2:199-205.
9. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease: a further report. BMJ. 1969;2:651-657.
10. Sartwell PE, Masi AT, Arthes FG, Greene GR, Smith HE. Thromboembolism and oral contraceptives: an epidemiologic case-control study. Am J Epidemiol. 1969; 90:365-380.
11. Hennekens CH, Buring JE. Epidemiology in Medicine. Boston, Mass: Little Brown & Co Inc; 1987:34, 273.
12. Friedman GD. Primer of Epidemiology. 4th ed. New York, NY: McGraw-Hill Book Co; 1994:215.
13. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical Epidemiology. A Basic Science for Clinical Medicine. 2nd ed. Boston, Mass: Little Brown & Co Inc; 1991: 288-289, 292.
14. Colman RW, Hirsch J, Marder VJ, Salzman EW. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Philadelphia, Pa: JB Lippincott; 1994: 1283-1284.
15. Douketis JD, Ginsberg JS, Holbrook A, Crowther M, Duku EK, Burrows RF. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Intern Med. 1997;157: 1522-1530.
16. Miettinen OS. Theoretical Epidemiology: Principles of Occurrence Research in Medicine. New York, NY: John Wiley & Sons Inc; 1985:79.
17. Huisman MV, Büller HR, ten Cate JW, Vreeken J. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients: the Amsterdam General Practitioner Study. N Engl J Med. 1986;314:823-828.
18. Lensing AWA, Prandoni P, Brandjes D, et al. Accurate detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med. 1989;320:342-345.
19. Heijboer H, Büller HR, Lensing AWA, Turpie AGG, Colly LP, ten Cate JW. Comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. N Engl J Med. 1993;329:1365-1369.
20. Committee on Safety of Medicines. Combined Oral Contraceptives and Thromboembolism. London, England: CSM; 1995.
21. Lewis MA, Heinemann LAJ, MacRae KD, Bruppacher R, Spitzer WO, with the Transnational Research Group on Oral Contraceptives and the Health of Young Women. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception. 1996;54: 5-13.
22. Poulter NR, Farley TMM, Chang CL, Marmot MG, Meirik O. Authors' reply: safety of combined oral contraceptive pills. Lancet. 1996;347:547.
23. Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KWM, Rosendaal FR. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insights in coagulation. Am J Obstet Gynecol. 1997;177: 887-891.
24. Records Unit and Research Advisory Service of the Royal College of General Practitioners. Oral contraception and thrombo-embolic disease. J Coll Gen Pract. 1967; 13:267-279.
25. Inman WHW, Vessey MP. Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. BMJ. 1968; 2:193-199.
26. Boston Collaborative Drug Surveillance Programme. Oral contraceptives and venous thromboembolic disease, surgically confirmed gall-bladder disease, and breast tumours. Lancet. 1973;1:1399-1404.
27. Jick H, Slone D, Westerholm B, et al. Venous thromboembolic disease and ABO blood type: a cooperative study. Lancet. 1969;1:539-542.
28. Inman WHW, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. BMJ. 1970;2:203-209.
29. Böttiger LE, Westerholm B. Oral contraceptives and thromboembolic disease: Swedish experience. Acta Med Scand. 1971;190:455-463.
30. Sartwell PE. Oral contraceptives and thromboembolism: a further report. Am J Epidemiol. 1971;94:192-201.
31. Royal College of General Practitioners' Oral Contraception Study. Oral contraceptives, venous thrombosis and varicose veins. J R Coll Gen Pract. 1978;28: 393-399.
32. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. BMJ. 1986;292:526.
33. Stolley PD, Tonascia JA, Tockman MS, Sartwell PE, Rutledge AH, Jacobs MP. Thrombosis with low-estrogen oral contraceptives. Am J Epidemiol. 1975;102: 197-208.
34. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol. 1991;133:32-37.
35. Realini JP, Encarnacion CE, Chintapalli KN, Rees CR. Oral contraceptives and venous thromboembolism: a case-control study designed to minimize detection bias. J Am Board Fam Pract. 1997;10:315-321.
36. Rosenberg L, Begaud B, Bergman U, et al. What are the risks of third-generation oral contraceptives? are third-generation oral contraceptives safe? Hum Reprod. 1996;11:687-688.
37. Lidegaard Ø, Milsom I. Oral contraceptives and thrombotic diseases: impact of new epidemiological studies. Contraception. 1996;53:135-139.
38. Lidegaard Ø. Oral contraceptives and venous thromboembolism: an epidemiological review. Eur J Contracept Reprod Health Care. 1996;1:13-20.
39. Rekers H, Norpoth T, Michaels MA. Oral contraceptive use and venous thromboembolism: a consideration of the impact of bias and confounding factors on epidemiological studies. Eur J Contracept Reprod Health Care. 1996;1:21-30.